The Magazine for Sleep Professionals
Thursday, September 10, 2026
ZOLL announced today that it has appointed Eric Knudsen as its new Chief Executive Officer, effective April 1. Knudsen will succeed Jon Rennert, who served as ZOLL’s CEO for the past 10 years and will assume a new role as Executive Chairman of ZOLL’s Board of Directors. “As a global […]
ZOLL® has announced today that a new analysis of data from the remedē® System Pivotal Trial suggests favorable outcomes for heart failure (HF) patients with central sleep apnea (CSA). The analysis was performed post-hoc using a hierarchical endpoint comprised of mortality, HF hospitalization, and health status. The new analysis was […]
WatchPAT® with SleePATh® is a digital solution for clinicians which integrates automated subjective patient data with the WatchPAT® ONE home sleep study results for enhanced diagnosis, data management and analysis. It simplifies the patient journey, streamlines the clinical experience and enhances the diagnosis. It combines pre and post sleep study […]
ZOLL® Medical Corporation announced that it has successfully completed its previously announced acquisition of Itamar™ Medical Ltd. “We are pleased to announce the closing of the acquisition of Itamar and welcome its employees to the ZOLL family,” said Jon Rennert, ZOLL CEO. “Together, ZOLL and Itamar Medical will help more […]
ZOLL® Medical Corporation and Itamar™ Medical Ltd. announced that the two companies signed a definitive agreement under which ZOLL Medical will acquire all outstanding ordinary shares of Itamar Medical for a total value of approximately $538 million. Itamar Medical is focused on the development and commercialization of non-invasive medical devices […]
ZOLL® Medical Corporation announced that the peer-reviewed journal Nature and Science of Sleep has published five-year results from the remedē System Post Approval Study. The data show sustained safety and efficacy of transvenous phrenic nerve stimulation for the treatment of moderate to severe central sleep apnea (CSA). The remedē® System, the only implantable device […]
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has acquired Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA). CSA is a serious condition that is often associated with heart […]
New Z Vent Transport Ventilator and ZOLL Respond App Debut ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced the launch of the company’s Z Vent™ transport ventilator for pre- and intra-hospital use. Z Vent delivers a full range of ventilation options […]
ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today the receipt of a sole source contract from the Defense Logistics Agency to supply Propaq® M deployable vital signs monitors to the U.S. Air Force and the U.S. Army. “We are very […]
